Assessed for eligibility (n=71)

Slides:

Advertisements

Similar presentations

Math 145 August 5, Review Methods of Acquiring Data: 1. Census – obtaining information from each individual in the population. 2. Sampling – obtaining.

Advertisements

Supplemental Figure 1 A No. at risk T T T

Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):

Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.

Converting between metric weight units. Converting metric weights How many mg to 1 g? How many g to 1 kg? How many kg to 1 t? 1000 mg = 1 g 1000 g = 1.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

WEEK 1 You have 10 seconds to name…

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

SOF/VEL 400/100 mg qd N = 75 W24 SOF/VEL > 18 years Chronic HCV infection Genotype 1 to 6 Naïve or treatment-experienced No prior treatment with NS5A or.

Math 145 December 3, Review Methods of Acquiring Data: 1. Census – obtaining information from each individual in the population. 2. Sampling – obtaining.

Sglt-2 insulin Matthews D, Fulcher G, Perkovic V, et al. Ef  cacy and safety of canagliflozin,an inhibitor of sodium glucose co-transporter 2, added.

Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Dietary Protein Content on Weight Gain,

Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.

 Insulin Degludec  Ultra long action  Due to formation of soluble multihexamers at the injection site from which monomers gradually separate and are.

Genotype 1 HCV infection Stable immunosuppressive therapy

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.

Supplemental Figure S1 (A) (B) Any Statin ↓Randomisation

Taieb V, et al. Value Health Nov;18(7):A598.

Volume 26, Issue 2, Pages e2 (August 2017)

Figure 1. Consort flow diagram.

Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline.

Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.

Assessed for eligibility (n = 38)

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu,

Tips Need to Consider When Organizing a College Event

End point Muraglitazar 5 mg plus metformin (n=569)

Diabetes and Risk of CV Outcomes

Assessed for eligibility (N = )

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Patient disposition for the double-blind study period.

مدیریت استراتژيک منابع انسانی

Figure 4 Effect of dapagliflozin on HbA1c and body weight

SGLT2 Inhibitors in Phase 3 Trials

Rapid Entire Body Assessment تهیه کننده : دکتر مسعود مطلبی

Diabetes Journal Club Julie Shah.

Geir Smedslund, Ph.D.: Diakonhjemmet Hospital (DH)

ماجستير إدارة المعارض من بريطانيا

G. Michael Felker et al. JCHF 2014;2:

Macitentan in Pulmonary Hypertension Due To Left Ventricular Dysfunction: MELODY-1 Jean-Luc Vachièry, Marion Delcroix, Hikmet Al-Hiti, Michela Efficace,

Novel Approaches to T1D Management

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

The Role of the Kidney in Glucose Control

ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies

Pharmacotherapy for Diabetic Coronary Disease:

Ռազմավարական կառավարում

Volume 26, Issue 2, Pages e2 (August 2017)

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Flow of Patients Through Trial

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

SOF/VEL ± RBV in genotype 3 with compensated cirrhosis

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Effects of tumour size on response to treatment in the KPC model.

(A) Energy and (B) protein intake/day during hospitalisation and in follow-up. (A) Energy and (B) protein intake/day during hospitalisation and in follow-up.

Assessed for eligibility N = 15593

Effect of empagliflozin on efficacy parameters at week 18.

NT-proBNP calculator Age year Women Height cm Weight kg Hemoglobin

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

Presentation transcript:

Assessed for eligibility (n=71) Supplemental Figure 1. Enrollment Assessed for eligibility (n=71) Randomized (n=71) Allocation Allocated to Dapagliflozin (n=36) Allocated to Pioglitazone (n=35) Follow-Up No lost to follow up Adverse events (n=2) No lost to follow up Adverse events (n=1) Analysis 36 completed 24 week follow-up observation 35 completed 24 week follow-up observation

Supplemental Figure 2. ⊿Body weight (kg) ⊿Body weight (kg) r = 0.16, p = 0.35 r = 0.43, p < 0.05 ⊿HbA1c (%) ⊿HbA1c (%) Dapagliflozin Pioglitazone

Supplemental Figure 3. A B ⊿NT-proBNP (pg/mL) ⊿NT-proBNP (pg/mL) r = - 0.68, p < 0.01 r = - 0.36, p < 0.05 Baseline log converted ACR (log mg/g) Baseline NT-proBNP (pg/mL)